Evidence map›Paper›PMID 31413277›Full record

ArticleCell death & disease2019

The POU4F2/Brn-3b transcription factor is required for the hypertrophic response to angiotensin II in the heart.

Laura Mele, Lauren J Maskell, Daniel J Stuckey, James E Clark, Richard J Heads, Vishwanie S Budhram-Mahadeo

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Laura MeleMolecular Biology Development and Disease, UCL Institute of Cardiovascular Science, London, UK.
Lauren J MaskellMolecular Biology Development and Disease, UCL Institute of Cardiovascular Science, London, UK.
Daniel J StuckeyCentre for Advanced Biomedical Imaging (CABI), Division of Medicine, UCL Faculty of Medical Sciences, London, UK.
James E ClarkSchool of Cardiovascular Medicine and Sciences, Faculty of Life Sciences and Medicine, King's College, London, UK.
Richard J HeadsSchool of Cardiovascular Medicine and Sciences, Faculty of Life Sciences and Medicine, King's College, London, UK.
Vishwanie S Budhram-MahadeoMolecular Biology Development and Disease, UCL Institute of Cardiovascular Science, London, UK. v.budhram-mahadeo@ucl.ac.uk.
University College London · GBKing's College London · GB

Funding

British Heart Foundation FS/14/32/30729British Heart Foundation FS/15/33/31608British Heart Foundation FS/17/8/32664British Heart Foundation PG/08/074/255533British Heart Foundation PG/16/73/32364Medical Research Council MR/R026416/1
6 · The paper itself

Abstract

Adult hearts respond to increased workload such as prolonged stress or injury, by undergoing hypertrophic growth. During this process, the early adaptive responses are important for maintaining cardiac output whereas at later stages, pathological responses such as cardiomyocyte apoptosis and fibrosis cause adverse remodelling, that can progress to heart failure. Yet the factors that control transition from adaptive responses to pathological remodelling in the heart are not well understood. Here we describe the POU4F2/Brn-3b transcription factor (TF) as a novel regulator of adaptive hypertrophic responses in adult hearts since Brn-3b mRNA and protein are increased in angiotensin-II (AngII) treated mouse hearts with concomitant hypertrophic changes [increased heart weight:body weight (HW:BW) ratio]. These effects occur specifically in cardiomyocytes because Brn-3b expression is increased in AngII-treated primary cultures of neonatal rat ventricular myocytes (NRVM) or foetal heart-derived H9c2 cells, which undergo characteristic sarcomeric re-organisation seen in hypertrophic myocytes and express hypertrophic markers, ANP/βMHC. The Brn-3b promoter is activated by known hypertrophic signalling pathways e.g. p42/p44 mitogen-activated protein kinase (MAPK/ERK1/2) or calcineurin (via NFAT). Brn-3b target genes, e.g. cyclin D1, GLUT4 and Bax, are increased at different stages following AngII treatment, supporting distinct roles in cardiac responses to stress. Furthermore, hearts from male Brn-3b KO mutant mice display contractile dysfunction at baseline but also attenuated hypertrophic responses to AngII treatment. Hearts from AngII-treated male Brn-3b KO mice develop further contractile dysfunction linked to extensive fibrosis/remodelling. Moreover, known Brn-3b target genes, e.g. GLUT4, are reduced in AngII-treated Brn-3b KO hearts, suggesting that Brn-3b and its target genes are important in driving adaptive hypertrophic responses in stressed heart.

Indexed as

Angiotensin IIAnimalsAnimals, NewbornApoptosisbcl-2-Associated X ProteinCalcineurinCardiovascular DiseasesCyclin D1Gene Expression RegulationGlucose Transporter Type 4HumansHypertrophyMiceMice, KnockoutMyocardiumMyocytes, CardiacAngiotensin IIBax protein, ratbcl-2-Associated X ProteinCalcineurinCyclin D1Glucose Transporter Type 4Pou4f2 protein, ratRNA, Small InterferingSlc2a4 protein, ratTranscription Factor Brn-3B

Identifiers

PMID31413277
PMCPMC6694165
OpenAlexW2968510648

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.